Cargando…
Extracorporeal mesenchymal stromal cell therapy (SBI-101) in severe COVID-19 complicated by acute kidney injury
Autores principales: | Teixiera, J., Atta, M.G., Noureddine, L., Nguyen, S., O’Rourke, B., Tilles, A., Bornschlegl, S., LaPointe, E., Dietz, A., Nissenson, A., Blair, A., Parekkadan, B., Barcia, R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Society for Cell & Gene Therapy. Published by Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111903/ http://dx.doi.org/10.1016/S1465324921002772 |
Ejemplares similares
-
Extracorporeal Stromal Cell Therapy for Subjects With Dialysis-Dependent Acute Kidney Injury
por: Miller, Brian L.K., et al.
Publicado: (2018) -
Mesenchymal stromal cell delivery via an ex vivo bioreactor preclinical test system attenuates clot formation for intravascular application
por: O'Rourke, Brian, et al.
Publicado: (2021) -
Pharmacological effects of ex vivo mesenchymal stem cell immunotherapy in patients with acute kidney injury and underlying systemic inflammation
por: Swaminathan, Madhav, et al.
Publicado: (2021) -
Mesenchymal Stromal Cell Bioreactor for Ex Vivo Reprogramming of Human Immune Cells
por: Allen, Ashley, et al.
Publicado: (2020) -
Author Correction: Mesenchymal Stromal Cell Bioreactor for Ex Vivo Reprogramming of Human Immune Cells
por: Allen, Ashley, et al.
Publicado: (2020)